Omar E. Franco

mTOR inhibition augments antitumor immune effector response by reprogramming the TP53-mutant, immune-cold HNSCC tumor microenvironment

The findings demonstrate that mTORi with everolimus reverses multiple mechanisms of immune resistance and enhances anti-tumor T cell activity, and support mTORi as a rational therapeutic strategy for TP53-mutant HNSCC and for reprogramming the immune-resistant TME, particularly in patients who are likely to fail immuno...